Effect of the Refrigerator Storage Time on the Potency of Botox for Human Extensor Digitorum Brevis Muscle Paralysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose It is recommended that Botox be used within 5 hours of reconstitution, which results in substantial quantities being discarded. This is not only uneconomic, but also inconvenient for treating patients. The aim of this study was to determine the potencies of Botox used within 2 hours of reconstitution with unpreserved saline, the same Botox refrigerated (at +4ºC) 72 hours after reconstitution, and during the next 4 consecutive weeks (weeks 1, 2,3, and 4). This comparison was used to determine the length of refrigeration time during which reconstituted Botox will maintain the same efficacy as freshly reconstituted toxin. Methods Individual paralysis rates in the extensor digitorum brevis (EDB) compound muscle action potential (CMAP) amplitude and area were measured 1 week after injecting fresh reconstituted 2.5 MU of Botox on one side of the foot, and when the same quantity of Botox that had been refrigerated for a designated time (i.e., 72 h, or 1, 2, 3, or 4 weeks) into the other side of the foot. The EDB CMAP amplitude and area at 12 and 16 weeks postinjection were also measured to compare the efficacy durations in all five comparative groups. Results Ninety-four volunteers were divided into five groups according to the refrigerator storage time of the second Botox injection. The paralysis of the EDBs was significant for each injection of Botox, both fresh and refrigerated, with no statistically significant differences between them, regardless of the refrigeration time. There was a tendency toward increased CMAP amplitude and area at 12 or 16 weeks postinjection (p<0.0001). The duration of effective muscle paralysis did not differ significantly throughout the 16-week follow-up period between all five groups. Conclusions The potency of reconstituted Botox is not degraded by subsequent refrigeration for 4 weeks. However, there are definite concerns regarding its sterility, and hence its safety,since multiple withdrawals from the same vial over long periods can introduce bacterial contamination.
Abstract
Background and Purpose It is recommended that Botox be used within 5 hours of reconstitution, which results in substantial quantities being discarded. This is not only uneconomic, but also inconvenient for treating patients. The aim of this study was to determine the potencies of Botox used within 2 hours of reconstitution with unpreserved saline, the same Botox refrigerated (at +4ºC) 72 hours after reconstitution, and during the next 4 consecutive weeks (weeks 1, 2,3, and 4). This comparison was used to determine the length of refrigeration time during which reconstituted Botox will maintain the same efficacy as freshly reconstituted toxin. Methods Individual paralysis rates in the extensor digitorum brevis (EDB) compound muscle action potential (CMAP) amplitude and area were measured 1 week after injecting fresh reconstituted 2.5 MU of Botox on one side of the foot, and when the same quantity of Botox that had been refrigerated for a designated time (i.e., 72 h, or 1, 2, 3, or 4 weeks) into the other side of the foot. The EDB CMAP amplitude and area at 12 and 16 weeks postinjection were also measured to compare the efficacy durations in all five comparative groups. Results Ninety-four volunteers were divided into five groups according to the refrigerator storage time of the second Botox injection. The paralysis of the EDBs was significant for each injection of Botox, both fresh and refrigerated, with no statistically significant differences between them, regardless of the refrigeration time. There was a tendency toward increased CMAP amplitude and area at 12 or 16 weeks postinjection (p<0.0001). The duration of effective muscle paralysis did not differ significantly throughout the 16-week follow-up period between all five groups. Conclusions The potency of reconstituted Botox is not degraded by subsequent refrigeration for 4 weeks. However, there are definite concerns regarding its sterility, and hence its safety,since multiple withdrawals from the same vial over long periods can introduce bacterial contamination.
참고문헌 (49)
- Blasi J, "Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP- 25", Nature, 365, pp.160~163 (1993)
- Schiavo G, "Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds", FEBS Letters, 335, pp.99~103 (1993)
- Duchen LW, "An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse", Journal of the Neurological Sciences, 14, pp.47~60 (1971)
- Molgo J, "Presynaptic actions of botulinal neurotoxins at vertebrate neuromuscular junctions", Journal of Physiology (Paris), 84, pp.152~166 (1990)
- Brin MF, "Botulinum toxin: new and expanded indications", European Journal of Neurology, 4, pp.S59~S65 (1997)
- Ahn KY, "Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans", Plastic and Reconstructive Surgery, 105, pp.778~784 (2000)
- Carruthers J, "Botulinum toxin (botox) chemodenervation for facial rejuvenation", Facial Plastic Surgery Clinics of North America, 9, pp.197~204 (2001)
- Park MY, "Botulinum toxin type A treatment for contouring of the lower face", Dermatologic Surgery, 29, pp.477~483 (2003)
- Brin MF, "Botulinum toxin type A for pain and headache, In Scientific and Therapeutic Aspects of Botulinum Toxin" (2002), Lippincott Williams & Wilkins
- Naumann M, "Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial", BMJ, 323, pp.596~599 (2001)
- Klein AW, "Dilution and storage of botulinum toxin", Dermatologic Surgery, 24, pp.1179~1180 (1998)
- Gartlan MG, "Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage", Otolaryngology - Head and Neck Surgery, 108, pp.135~140 (1993)
- Sloop RR, "Human response to botulinum toxin injection: type B compared with type A", Neurology, 49, pp.189~194 (1997)
- Paik NJ, "Reduced potency after refrigerated storage of botulitum toxin A: human extensor digitorum brevis muscle study", Movement Disorders, 21, pp.1759~1763 (2006)
- Sloop RR, "Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use", Neurology, 48, pp.249~253 (1997)
- Yang GC, "Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox", Archives of Facial Plastic Surgery, 10, pp.273~279 (2008)
- Garcia A, "Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study", Dermatologic Surgery, 22, pp.39~43 (1996)
- Hexsel DM, "Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application", Dermatologic Surgery, 29, pp.523~529 (2003)
- Dolman CE, "Botulism as a world problem, In Botulism" (1964), U.S. Dept. of Health, Education, and Welfare, Public Health Service
- Hambleton P, "Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use", Journal of Neurology, 239, pp.16~20 (1992)
- Jessell TM, "Synaptic transmission: a bidirectional and self-modifiable form of cell-cell communication", Cell, 72(Suppl), pp.1~30 (1993)
- Montecucco C, "Tetanus and botulism neurotoxins: a new group of zinc proteases", Trends in Biochemical Sciences, 18, pp.324~327 (1993)
- Schiavo G, "Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus", Annals of the New York Academy of Sciences, 710, pp.65~75 (1994)
- Shaari CM, "Quantifying how location and dose of botulinum toxin injections affect muscle paralysis", Muscle & Nerve, 16, pp.964~969 (1993)
- Borodic GE, "Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy", Ophthalmic Plastic & Reconstructive Surgery, 7, pp.54~60 (1991)
- Borodic GE, "Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle", Head & Neck, 14, pp.33~37 (1992)
- Hambleton P, "Antitoxins and botulinum toxin treatment", BMJ, 304, pp.959~960 (1992)
- Zuber M, "Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance", Neurology, 43, pp.1715~1718 (1993)
- Greene P, "Potency of frozen", thawed botulinum toxin type A in the treatment of torsion dystonia, 1993, pp.109, 968~969
- First ER, "Dose standardisation of botulinum toxin", The Lancet, 343, pp.1035~ (1994)
- Pickett AM, "Dose standardisation of botulinum toxin", The Lancet, 344, pp.474~475 (1994)
- Hughes R, "Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin", The Journal of Physiology, 160, pp.221~233 (1962)
- Eleopra R, "The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans", Movement Disorders, 12, pp.89~94 (1997)
- Kim HS, "Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis", Developmental Medicine & Child Neurology, 45, pp.200~206 (2003)
- Glocker FX, "Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units", Neuroscience Letters, 187, pp.161~164 (1995)
- Hesse S, "Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients", Neuroscience Letters, 201, pp.37~40 (1995)
- Holds JB, "Botulinum A toxin injection. Failures in clinical practice and a biomechanical system for the study of toxin-induced paralysis", Ophthalmic Plastic & Reconstructive Surgery, 6, pp.252~259 (1990)
- Sloop RR, "Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A", Neurology, 46, pp.1382~1386 (1996)
- Kauffman JA, "Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction", Toxicology and Applied Pharmacology, 79, pp.211~217 (1985)
- Frueh BR, "Treatment of blepharospasm with botulinum toxin. A preliminary report", Archives of Ophthalmology, 102, pp.1464~1468 (1984)
- Borodic GE, "Blepharospasm and its treatment, with emphasis on the use of botulinum toxin", Plastic and Reconstructive Surgery, 83, pp.546~554 (1989)
- Pearce LB, "Measurement of botulinum toxin activity: evaluation of the lethality assay", Toxicology and Applied Pharmacology, 128, pp.69~77 (1994)
- Pearce LB, "The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin", Toxicon, 33, pp.217~227 (1995)
- Kessler KR, "The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A", Movement Disorders, 12, pp.95~99 (1997)
- Gordon PH, "Extensor digitorum brevis test and resistance to botulinum toxin type A", Muscle & Nerve, 26, pp.828~831 (2002)
- Houser MK, "Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A", Journal of Neurology, Neurosurgery & Psychiatry, 64, pp.577~580 (1998)
- Inagi K, "An anatomic study of the rat larynx: establishing the rat model for neuromuscular function", Otolaryngology - Head and Neck Surgery, 118, pp.74~81 (1998)
- Hamjian JA, "Serial neurophysiological studies of intramuscular botulinum-A toxin in humans", Muscle & Nerve, 17, pp.1385~1392 (1994)
- Park MY, "Botulinum toxin a for the treatment of hyperkinetic wrinkle lines", Plastic and Reconstructive Surgery, 112(5 Suppl), pp.148S~150S (2003)